JP2007051155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007051155A5 JP2007051155A5 JP2006291545A JP2006291545A JP2007051155A5 JP 2007051155 A5 JP2007051155 A5 JP 2007051155A5 JP 2006291545 A JP2006291545 A JP 2006291545A JP 2006291545 A JP2006291545 A JP 2006291545A JP 2007051155 A5 JP2007051155 A5 JP 2007051155A5
- Authority
- JP
- Japan
- Prior art keywords
- ylmethyl
- isoxazol
- octahydro
- pyrido
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 30
- -1 hydroxy, amino Chemical group 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 206010012289 Dementia Diseases 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 201000000980 schizophrenia Diseases 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- PJMUNJOFKTZCIW-UHFFFAOYSA-N 3-[7-[[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC2=NC=C(C=C2)CN2CCCC2 PJMUNJOFKTZCIW-UHFFFAOYSA-N 0.000 claims 5
- YYWGUWVWUGWQPY-UHFFFAOYSA-N 3-[7-[[5-[(2-methylpyrrolidin-1-yl)methyl]pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC1=NC=C(C=C1)CN1C(CCC1)C YYWGUWVWUGWQPY-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 230000036651 mood Effects 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000022821 personality disease Diseases 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- GXAUMTXKKVKIJZ-UHFFFAOYSA-N 3-[7-[[5-(piperidin-1-ylmethyl)pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1h-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound C1CC2C(C3=NOC=C3)NCCN2CC1COC(N=C1)=CC=C1CN1CCCCC1 GXAUMTXKKVKIJZ-UHFFFAOYSA-N 0.000 claims 3
- GFNMLOFOXILWJE-UHFFFAOYSA-N 3-[7-[[6-(pyrrolidin-1-ylmethyl)pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC1=NC(=CC=C1)CN1CCCC1 GFNMLOFOXILWJE-UHFFFAOYSA-N 0.000 claims 3
- 206010026749 Mania Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010034912 Phobia Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- MSOXFHMCXLIFRJ-UHFFFAOYSA-N 3-[7-[[5-[(2-methylaziridin-1-yl)methyl]pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC1=NC=C(C=C1)CN1C(C1)C MSOXFHMCXLIFRJ-UHFFFAOYSA-N 0.000 claims 2
- LPLFRMNZSFKRJA-UHFFFAOYSA-N 4-[[6-[[1-(1,2-oxazol-3-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-yl]methoxy]pyridin-2-yl]methyl]morpholine Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC1=NC(=CC=C1)CN1CCOCC1 LPLFRMNZSFKRJA-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 229940025084 amphetamine Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 229960003920 cocaine Drugs 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims 1
- AMNSTJVLSCINFN-JCUDRXCFSA-N 3-[(7R,9aS)-7-[[6-[[(2S,5S)-2,5-dimethylpyrrolidin-1-yl]methyl]pyridin-2-yl]oxymethyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-5-fluoro-1,2-benzoxazole Chemical compound C[C@@H]1N([C@H](CC1)C)CC1=CC=CC(=N1)OC[C@@H]1CC[C@@H]2N(CCN(C2)C2=NOC3=C2C=C(C=C3)F)C1 AMNSTJVLSCINFN-JCUDRXCFSA-N 0.000 claims 1
- KETKNCJQPBIFRE-FUCAVZNHSA-N 3-[(7R,9aS)-7-[[6-[[(2S,6S)-2,6-dimethylpiperidin-1-yl]methyl]pyridin-2-yl]oxymethyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-5-fluoro-1,2-benzoxazole Chemical compound C[C@@H]1N([C@H](CCC1)C)CC1=CC=CC(=N1)OC[C@@H]1CC[C@@H]2N(CCN(C2)C2=NOC3=C2C=C(C=C3)F)C1 KETKNCJQPBIFRE-FUCAVZNHSA-N 0.000 claims 1
- YDOQLJXCEUEJNJ-UHFFFAOYSA-N 3-[7-[[5-(1,3-thiazolidin-3-ylmethyl)pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC1=NC=C(C=C1)CN1CSCC1 YDOQLJXCEUEJNJ-UHFFFAOYSA-N 0.000 claims 1
- PSCOJTKUFQSHFS-UHFFFAOYSA-N 3-[7-[[5-(imidazol-1-ylmethyl)pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC1=NC=C(C=C1)CN1C=NC=C1 PSCOJTKUFQSHFS-UHFFFAOYSA-N 0.000 claims 1
- FVCBUSCIOBOAAE-UHFFFAOYSA-N 3-[7-[[5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC2=NC=C(C=C2)CN2CCN(CCC2)C FVCBUSCIOBOAAE-UHFFFAOYSA-N 0.000 claims 1
- YLWDZDORIQWYNS-UHFFFAOYSA-N 3-[7-[[5-[[2-(methoxymethyl)pyrrolidin-1-yl]methyl]pyridin-2-yl]oxymethyl]-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-1-yl]-1,2-oxazole Chemical compound O1N=C(C=C1)C1C2N(CCN1)CC(CC2)COC1=NC=C(C=C1)CN1C(CCC1)COC YLWDZDORIQWYNS-UHFFFAOYSA-N 0.000 claims 1
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012374 Depressed mood Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010029897 Obsessive thoughts Diseases 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000036750 Schizophrenia, residual type Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000031424 hyperprolactinemia Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- BAYGVKFLEMETOJ-UHFFFAOYSA-N n-[[6-[[2-(1,2-benzoxazol-3-yl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-yl]methoxy]pyridin-2-yl]methyl]-6-methoxypyridin-3-amine Chemical compound C1=NC(OC)=CC=C1NCC1=CC=CC(OCC2CN3CCN(CC3CC2)C=2C3=CC=CC=C3ON=2)=N1 BAYGVKFLEMETOJ-UHFFFAOYSA-N 0.000 claims 1
- PJRSCKASIOSASZ-UHFFFAOYSA-N n-[[6-[[2-(1,2-benzoxazol-3-yl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-yl]methoxy]pyridin-3-yl]methyl]-1h-pyrazol-5-amine Chemical compound C=1C=C(OCC2CN3CCN(CC3CC2)C=2C3=CC=CC=C3ON=2)N=CC=1CNC1=CC=NN1 PJRSCKASIOSASZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000024817 paranoid personality disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- 229960002695 phenobarbital Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000022170 stress incontinence Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 201000006137 substance-induced psychosis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 0 C**(C)(C)N(*)* Chemical compound C**(C)(C)N(*)* 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45392503P | 2003-03-12 | 2003-03-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506261A Division JP3910627B2 (ja) | 2003-03-12 | 2004-02-23 | ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007051155A JP2007051155A (ja) | 2007-03-01 |
| JP2007051155A5 true JP2007051155A5 (https=) | 2007-04-12 |
Family
ID=32990837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506261A Expired - Fee Related JP3910627B2 (ja) | 2003-03-12 | 2004-02-23 | ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体 |
| JP2006291545A Pending JP2007051155A (ja) | 2003-03-12 | 2006-10-26 | ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506261A Expired - Fee Related JP3910627B2 (ja) | 2003-03-12 | 2004-02-23 | ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7345038B2 (https=) |
| EP (1) | EP1608648B1 (https=) |
| JP (2) | JP3910627B2 (https=) |
| KR (2) | KR100767854B1 (https=) |
| CN (1) | CN100389115C (https=) |
| AP (1) | AP2005003390A0 (https=) |
| AR (1) | AR043537A1 (https=) |
| AU (2) | AU2004220327B2 (https=) |
| BR (1) | BRPI0408248A (https=) |
| CA (1) | CA2518740C (https=) |
| EA (1) | EA009527B1 (https=) |
| EC (1) | ECSP056011A (https=) |
| GT (1) | GT200400041A (https=) |
| HR (1) | HRP20050798A2 (https=) |
| IL (1) | IL170290A (https=) |
| MA (1) | MA27747A1 (https=) |
| MX (1) | MXPA05009660A (https=) |
| NL (1) | NL1025710C2 (https=) |
| NO (1) | NO20054095L (https=) |
| OA (1) | OA13038A (https=) |
| PA (1) | PA8597501A1 (https=) |
| PE (1) | PE20041057A1 (https=) |
| PL (1) | PL378749A1 (https=) |
| RS (1) | RS20050692A (https=) |
| TN (1) | TNSN05224A1 (https=) |
| TW (1) | TW200502234A (https=) |
| UA (1) | UA78437C2 (https=) |
| UY (1) | UY28225A1 (https=) |
| WO (1) | WO2004081007A1 (https=) |
| ZA (1) | ZA200506373B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6994726B2 (en) * | 2004-05-25 | 2006-02-07 | Calcitec, Inc. | Dual function prosthetic bone implant and method for preparing the same |
| UA83509C2 (en) * | 2003-10-15 | 2008-07-25 | Оси Фармасьютикалз, Инк. | Imidazopyrazines as tyrosine kinase inhibitors |
| EP1715868A1 (en) * | 2004-01-29 | 2006-11-02 | Pfizer Products Incorporated | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
| EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| MX2007002842A (es) * | 2004-09-10 | 2007-04-30 | Pfizer Prod Inc | Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol. |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| US20110046144A1 (en) * | 2008-01-18 | 2011-02-24 | Mulvihill Mark J | Imidazopyrazinol derivatives for the treatment of cancers |
| ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| US8513415B2 (en) | 2009-04-20 | 2013-08-20 | OSI Pharmaceuticals, LLC | Preparation of C-pyrazine-methylamines |
| EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
| US9394290B2 (en) * | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2016115282A1 (en) * | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| WO2023083445A1 (en) | 2021-11-10 | 2023-05-19 | Symrise Ag | Compositions comprising trpm8 agonistic cooling agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008148A1 (en) * | 1989-01-23 | 1990-07-26 | Pfizer Inc. | Bis-aza-bicyclic anxiolytic agents |
| US5167034A (en) * | 1990-06-18 | 1992-11-24 | International Business Machines Corporation | Data integrity for compaction devices |
| US5157034A (en) | 1991-02-27 | 1992-10-20 | Pfizer Inc. | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines |
| FI941377A0 (fi) * | 1991-09-25 | 1994-03-24 | Pfizer | Neuroleptisiä 2-substituoituja perhydro-1-H-pyrido/1,2-a/-pyratsiineja |
| DE69326767T2 (de) * | 1992-06-16 | 2000-03-02 | Pfizer Inc., New York | Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica |
| WO1996010570A1 (en) * | 1994-09-30 | 1996-04-11 | Pfizer Inc. | NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES |
| KR100589872B1 (ko) | 1997-05-30 | 2006-06-15 | 뉴로서치 에이/에스 | 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 |
| PA8469101A1 (es) * | 1998-04-09 | 2000-09-29 | Pfizer Prod Inc | Ligandos azabiciclicos de receptores 5ht1 |
| US6608084B1 (en) | 1998-08-26 | 2003-08-19 | Aventis Pharma Ltd. | Aza-bicycles which modulate the inhibition of cell adhesion |
| ID29028A (id) | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
| ES2253930T3 (es) | 1998-09-18 | 2006-06-01 | ABBOTT GMBH & CO. KG | 4-aminopirrolopirimidinas como inhibidores de quinasa. |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| ATE278674T1 (de) | 1999-03-12 | 2004-10-15 | Boehringer Ingelheim Pharma | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
| EP1177792A3 (en) * | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
-
2004
- 2004-02-23 KR KR1020057016859A patent/KR100767854B1/ko not_active Expired - Fee Related
- 2004-02-23 CA CA2518740A patent/CA2518740C/en not_active Expired - Fee Related
- 2004-02-23 UA UAA200508639A patent/UA78437C2/uk unknown
- 2004-02-23 WO PCT/IB2004/000499 patent/WO2004081007A1/en not_active Ceased
- 2004-02-23 AU AU2004220327A patent/AU2004220327B2/en not_active Ceased
- 2004-02-23 BR BRPI0408248-6A patent/BRPI0408248A/pt not_active IP Right Cessation
- 2004-02-23 EP EP04713592A patent/EP1608648B1/en not_active Expired - Lifetime
- 2004-02-23 CN CNB2004800066516A patent/CN100389115C/zh not_active Expired - Fee Related
- 2004-02-23 MX MXPA05009660A patent/MXPA05009660A/es active IP Right Grant
- 2004-02-23 AP AP2005003390A patent/AP2005003390A0/xx unknown
- 2004-02-23 RS YUP-2005/0692A patent/RS20050692A/sr unknown
- 2004-02-23 JP JP2006506261A patent/JP3910627B2/ja not_active Expired - Fee Related
- 2004-02-23 HR HR20050798A patent/HRP20050798A2/hr not_active Application Discontinuation
- 2004-02-23 EA EA200501148A patent/EA009527B1/ru not_active IP Right Cessation
- 2004-02-23 PL PL378749A patent/PL378749A1/pl not_active Application Discontinuation
- 2004-02-23 OA OA1200500259A patent/OA13038A/en unknown
- 2004-02-23 KR KR1020077013527A patent/KR20070074667A/ko not_active Withdrawn
- 2004-03-08 PA PA20048597501A patent/PA8597501A1/es unknown
- 2004-03-09 PE PE2004000256A patent/PE20041057A1/es not_active Application Discontinuation
- 2004-03-10 AR ARP040100770A patent/AR043537A1/es not_active Application Discontinuation
- 2004-03-11 GT GT200400041A patent/GT200400041A/es unknown
- 2004-03-11 UY UY28225A patent/UY28225A1/es not_active Application Discontinuation
- 2004-03-11 TW TW093106481A patent/TW200502234A/zh unknown
- 2004-03-12 NL NL1025710A patent/NL1025710C2/nl not_active IP Right Cessation
- 2004-03-12 US US10/800,328 patent/US7345038B2/en not_active Expired - Fee Related
-
2005
- 2005-08-10 ZA ZA200506373A patent/ZA200506373B/en unknown
- 2005-08-15 IL IL170290A patent/IL170290A/en not_active IP Right Cessation
- 2005-09-02 NO NO20054095A patent/NO20054095L/no unknown
- 2005-09-12 EC EC2005006011A patent/ECSP056011A/es unknown
- 2005-09-12 TN TNP2005000224A patent/TNSN05224A1/fr unknown
- 2005-09-12 MA MA28495A patent/MA27747A1/fr unknown
-
2006
- 2006-10-26 JP JP2006291545A patent/JP2007051155A/ja active Pending
-
2010
- 2010-07-23 AU AU2010203303A patent/AU2010203303A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007051155A5 (https=) | ||
| AU2022206693B2 (en) | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor | |
| US11168070B2 (en) | Therapeutic compounds and uses thereof | |
| CN102482278B (zh) | 作为pi3k抑制剂的嘧啶酮类 | |
| US10183009B2 (en) | Therapeutic compounds and uses thereof | |
| JP6427257B2 (ja) | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン | |
| JP6832846B2 (ja) | ヘテロ環化合物およびその用途 | |
| US10155764B2 (en) | Therapeutic compounds and uses thereof | |
| JP5901535B2 (ja) | 酵素ｐｄｅ１０ａ阻害剤としてのヘテロ芳香族フェニルイミダゾール誘導体 | |
| EP3218376B1 (en) | Bromodomain inhibitors and uses thereof | |
| JP5698761B2 (ja) | 酵素ｐｄｅ１０ａ阻害剤としての２−アリールイミダゾール誘導体 | |
| JP2021054843A (ja) | トロポミオシン関連キナーゼ（ｔｒｋ）阻害剤 | |
| JP6814730B2 (ja) | 治療用化合物およびその使用 | |
| KR20100110804A (ko) | 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진 | |
| JP3910627B2 (ja) | ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体 | |
| US20190290637A1 (en) | New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors | |
| CN121002030A (zh) | 作为毒蕈碱型乙酰胆碱受体m4的正向别构调节剂的噻唑并吡啶衍生物 | |
| CN120936610A (zh) | 可用于治疗神经障碍和精神障碍的作为毒蕈碱型乙酰胆碱受体m4正向别构调节剂的1,6-萘啶衍生物 | |
| TW202530214A (zh) | 作為Ｐ１３Ｋα抑制劑之三環化合物 | |
| HK1177208B (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
| HK1242695B (zh) | 作為用於治療癌症的pcaf和gcn5抑制劑的式(i)的酞嗪衍生物 |